REG - Spectral MD Holdings - Exercise of Options

Spectral MD HoldingsAnnouncement

12/10/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221012:nRSL6915Ca&default-theme=true

RNS Number : 6915C  Spectral MD Holdings, Ltd.  12 October 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Exercise of Options

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI algorithms and optical
technology for faster and more accurate treatment decisions in wound care,
announces the exercise of options by certain employees of the Company (the
"Employees").

The Employees have exercised options over an aggregate of 152,500 shares of
common stock of US$0.001 each in the Company ("Common Stock") at various
exercise prices between US$0.10 and US$0.21 per share of Common Stock.
Accordingly, the Employees will be issued 152,500 shares of Common Stock in
the Company.

The Company will apply for 152,500 shares of Common Stock to be admitted to
trading on AIM, with admission expected to take place at 8:00 a.m. on or
around 17 October 2022 ("Admission"). The shares of Common Stock will
rank pari passu in all respects with existing Common Stock.

Following Admission, the total number of shares of Common Stock in issue will
be 136,249,564, with one voting right per share of Common Stock. Therefore,
the total number of voting rights in the Company will be 136,249,564.

Consequently, the above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the Company's Certificate of Incorporation.

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                      investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                           via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                         Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                   Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland /

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson                  Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

 Alice Woodings                                    +44 (0)7407 804 654

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEALEAFALAFFA